NCT06812481 Anticholinergic Burden and Osteoporosis in Rheumatoid Arthritis
| NCT ID | NCT06812481 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Balikesir University |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-09-15 |
| Primary Completion | 2025-11-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-09-15 with a primary completion date of 2025-11-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory rheumatological disease. Use of corticosteroids for more than 3 months in RA treatment is considered an important risk factor in terms of developing secondary osteoporosis and increasing the risk of fracture. The cumulative effect of taking one or more drugs with anticholinergic properties is called anticholinergic load. It is stated that anticholinergic load also increases the risk of fracture in individuals. The aim of this study is to investigate the effects of drugs used by patients with Rheumatoid Arthritis (RA) on anticholinergic load and fracture risk. The Fracture Risk Assessment Tool (FRAX) will be used to assess fracture risk in patients. Materials and methods: The study was planned as a prospective cohort study. The study will included 100 patients who were followed up as outpatients with rheumatoid arthritis diagnosis in the physical medicine and rehabilitation clinic between 2024-2025. Patients of both genders and over 18 years of age diagnosed with rheumatoid arthritis will be included in the study. Patients with systemic diseases or medications affecting bone metabolism and those with metallic materials in the hip or lumbar vertebrae affecting bone mineral density measurement will be excluded from the study. Demographic characteristics, systemic diseases, medications used, bone density measurement and blood test values of the patients will be recorded. Patients taking multiple medications with anticholinergic effects create an anticholinergic burden. The Anticholinergic Drug Scale, Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale will be used to measure anticholinergic burden in the study.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with rheumatoid arthritis Exclusion Criteria: * Kemik metabolizmasını etkileyen sistemik hastalıkları veya ilaçları kullanan hastalar, * Kemik mineral yoğunluk ölçümünü etkileyen kalça veya lomber vertebralarda metalik materyalleri olan hastalar
Contact & Investigator
Bilal UYSAL, assistant prof.
PRINCIPAL INVESTIGATOR
Balikesir University
Frequently Asked Questions
Who can join the NCT06812481 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06812481 currently recruiting?
Yes, NCT06812481 is actively recruiting participants. Contact the research team at bilaluysal@gmail.com for enrollment information.
Where is the NCT06812481 trial being conducted?
This trial is being conducted at Balıkesir, Turkey (Türkiye).
Who is sponsoring the NCT06812481 clinical trial?
NCT06812481 is sponsored by Balikesir University. The principal investigator is Bilal UYSAL, assistant prof. at Balikesir University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.